Masterclass: Transforming Psoriasis Care: Oral IL-23 Therapy and the Next Frontier in Patient-Centered Care

Psoriasis is a chronic autoimmune disease that affects approximately 8 million people in the US and places a substantial physical, psychological, and social burden on patients. [i]Despite therapeutic advances, management remains difficult due to poor adherence and patient dissatisfaction with current options. Injectable biologics offer durable control but are often limited by barriers such as injection fatigue, needle aversion, and costs. Oral therapies provide a convenient alternative by targeting systemic inflammation without injections. This session will appropriately position these therapies by comparing efficacy and safety across oral and injectable agents, and outline strategies for determining which patients are most likely to benefit from oral versus injectable approaches. After participating in this educational initiative, learners should be able to: • Examine limitations of injectable biologics in psoriasis, including barriers to adherence and patient preference for non-injectable options • Assess the safety/efficacy data and mechanisms of action of current and emerging oral therapies for moderate-to-severe PsO, including head-to-head comparisons and long-term data • Identify strategies to determine when patients may benefit from oral versus injectable treatment approaches Supported by an educational grant from Johnson & Johnson.